Fundraising Fox
Bluejaytx
acquired by Mirum PharmaceuticalsSan Mateo, US · Founded 2019 · 11 known investors
Find your way into Bluejaytx
Sign up to see every warm intro you have to Bluejaytx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bluejaytx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Mirum Pharmaceuticals, Inc. December 2025 · $620M ($250M cash and $370M stock upfront, plus up to $200M in milestones (~$820M total)) · source ↗
Bluejay is a biotechnology company focused on therapeutic development. The page centers on its founder's background in drug discovery and life science venture investing but gives limited detail on the company's specific products.
Founders & leadership
Bluejaytx was founded in 2019 by Keting Chu.
Investors · 11
How we know: Frazier Life Sciences's portfolio page · globenewswire.com · Not right? Tell us
How we know: RA Capital's portfolio page · globenewswire.com · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · globenewswire.com · Not right? Tell us
How we know: globenewswire.com · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Also in the syndicate · 2
Reported raises · per SEC filings
Form D private placements$221.7M disclosed across 3 rounds · 2021–2024
▶$182MraisedMay 2024 · 19 investors · Other TechnologyRule 506(b)
- Dan EstesDirector
- Pascal KroteeDirector
- Jianqing LiDirector
- Keting ChuExecutive Officer, Director
- Alon LazarusDirector
- Dajun YangDirector
- Offering amount
- $182M
- Amount sold
- $182M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$20.5MraisedAug 2022 · 9 investors · Other TechnologyRule 506(b)
- Keting ChuExecutive Officer, Director
- Dajun YangDirector
- Nancy HongDirector
- Alon LazarusDirector
- William J. RutterDirector
- Ting JiaDirector
- Wen ChenDirector
- Offering amount
- $41.2M
- Amount sold
- $20.5M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$19.2MraisedJun 2021 · 6 investors · Other TechnologyRule 506(b)
- Keting ChuExecutive Officer, Director
- Offering amount
- $24.2M
- Amount sold
- $19.2M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Bluejaytx do?
- Bluejay is a biotechnology company focused on therapeutic development. The page centers on its founder's background in drug discovery and life science venture investing but gives limited detail on the company's specific products.
- Who founded Bluejaytx?
- Bluejaytx was founded by Keting Chu in 2019.
- Who are Bluejaytx's investors?
- Bluejaytx's investors include Frazier Life Sciences, RA Capital, RiverVest Venture Partners, Wellington Management, Frazier Healthcare Partners, HBM Healthcare Investments, Novo Holdings, T. Rowe Price and 1 more.
- How much funding has Bluejaytx raised?
- Bluejaytx has disclosed $221.7M raised across 3 rounds.
- Who acquired Bluejaytx?
- Bluejaytx was acquired by Mirum Pharmaceuticals.
- Where is Bluejaytx headquartered?
- Bluejaytx is headquartered in San Mateo, US.